PRMT5 and B-cell non-Hodgkin lymphoma: The PRMT5 inhibitors, GSK3326595 and JNJ-64619178, are being evaluated in clinical trials in relapsed/refractory B-cell NHL including DLBCL (NCT02783300 and NCT03573310, respectively).